Experienced in Arterial Embolism

Dr. Sarika Jain

Thoracic Surgery | General Surgery | Vascular Surgery
Faculty Physicians And Surgeons Of Llusm
12021 Jacaranda Ave, 
Hesperia, CA 
Experienced in Arterial Embolism
Faculty Physicians And Surgeons Of Llusm
12021 Jacaranda Ave, 
Hesperia, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sarika Jain is a Thoracic Surgeon and a General Surgeon in Hesperia, California. Dr. Jain is rated as an Experienced provider by MediFind in the treatment of Arterial Embolism. Her top areas of expertise are Breast Cancer, Arterial Embolism, and Heart Bypass Surgery.

Her clinical research consists of co-authoring 20 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Thoracic Surgery
General Surgery
Vascular Surgery
Licenses
Thoracic Surgery (Cardiothoracic Vascular Surgery) in CA
Hospital Affiliations
Providence St Mary Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D

Locations

FACULTY PHYSICIANS AND SURGEONS OF LLUSM
12021 Jacaranda Ave, Hesperia, CA 92345

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Drug
Study Drugs: Endoxifen Hydrochloride, Tamoxifen Citrate
Study Phase: Phase 2
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A randoMized phAse II trIal of fulvestraNt wiTh or Without Ribociclib After Progression on AntI-estrogeN Therapy Plus Cyclin-dependent Kinase 4/6 Inhibition in Patients With Unresectable or Metastatic Hormone Receptor +, HER2 - Breast Cancer (MAINTAIN Trial)
A randoMized phAse II trIal of fulvestraNt wiTh or Without Ribociclib After Progression on AntI-estrogeN Therapy Plus Cyclin-dependent Kinase 4/6 Inhibition in Patients With Unresectable or Metastatic Hormone Receptor +, HER2 - Breast Cancer (MAINTAIN Trial)
Enrollment Status: Completed
Publish Date: December 06, 2024
Intervention Type: Drug
Study Drugs: LEE-011, Fulvestrant
Study Phase: Phase 2
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drugs: Capecitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
Phase I/Ib Study of Nivolumab and Veliparib in Patients With Advanced Solid Tumors and Lymphoma With and Without Alterations in Selected DNA Repair Genes
Phase I/Ib Study of Nivolumab and Veliparib in Patients With Advanced Solid Tumors and Lymphoma With and Without Alterations in Selected DNA Repair Genes
Enrollment Status: Completed
Publish Date: June 12, 2024
Intervention Type: Biological, Other, Drug
Study Drugs: Nivolumab, Veliparib
Study Phase: Phase 1
A Phase II Window of Opportunity Trial of Ipilimumab and Nivolumab in Metastatic Recurrent HER2- Inflammatory Breast Cancer (IBC) The Win Trial
A Phase II Window of Opportunity Trial of Ipilimumab and Nivolumab in Metastatic Recurrent HER2- Inflammatory Breast Cancer (IBC) The Win Trial
Enrollment Status: Terminated
Publish Date: July 16, 2020
Intervention Type: Biological, Other
Study Phase: Phase 2
Phase II Study of Pembrolizumab and Capecitabine for Advanced Triple Negative and Hormone-Refractory Breast Cancer
Phase II Study of Pembrolizumab and Capecitabine for Advanced Triple Negative and Hormone-Refractory Breast Cancer
Enrollment Status: Unknown
Publish Date: July 13, 2020
Intervention Type: Other, Drug, Biological
Study Drugs: Capecitabine, Pembrolizumab
Study Phase: Phase 2
A Phase II, Open Label Study to Evaluate Denosumab in Patients With ER and/or PR-Positive, HER2-Negative Metastatic Breast Cancer (MBC) With Bone Metastases and Detectable Circulating Tumor Cells (CTCs)
A Phase II, Open Label Study to Evaluate Denosumab in Patients With ER and/or PR-Positive, HER2-Negative Metastatic Breast Cancer (MBC) With Bone Metastases and Detectable Circulating Tumor Cells (CTCs)
Enrollment Status: Terminated
Publish Date: November 20, 2018
Intervention Type: Biological, Other
Study Phase: Phase 2
View 8 Less Clinical Trials

20 Total Publications

Intracardiac echocardiography from coronary sinus.
Intracardiac echocardiography from coronary sinus.
Journal: Journal of cardiovascular electrophysiology
Published: July 08, 2022
Similar Doctors
Distinguished in Arterial Embolism
Dr. Ahmed M. Abou-Zamzam
Vascular Surgery | General Surgery
Distinguished in Arterial Embolism
Dr. Ahmed M. Abou-Zamzam
Vascular Surgery | General Surgery

Faculty Physicians And Surgeons Of Llusm

11234 Anderson St, 
Loma Linda, CA 
 (29.0 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ahmed Abou-Zamzam is a Vascular Surgeon and a General Surgeon in Loma Linda, California. Dr. Abou-Zamzam is rated as a Distinguished provider by MediFind in the treatment of Arterial Embolism. His top areas of expertise are Carotid Artery Disease, Peripheral Artery Disease, Arterial Embolism, Carotid Artery Surgery, and Osteotomy.

Distinguished in Arterial Embolism
Dr. William J. Foley
Vascular Surgery
Distinguished in Arterial Embolism
Dr. William J. Foley
Vascular Surgery

Southern California Vascular Associates Inc

1310 W Stewart Dr, Suite 406, 
Orange, CA 
 (58.8 miles away)
714-532-0793
Languages Spoken:
English
See accepted insurances

William Foley is a Vascular Surgeon in Orange, California. Dr. Foley is rated as a Distinguished provider by MediFind in the treatment of Arterial Embolism. His top areas of expertise are Idiopathic Edema, Arterial Embolism, Carotid Artery Disease, Gangrene, and Carotid Artery Surgery.

Distinguished in Arterial Embolism
Dr. Fred A. Weaver
Vascular Surgery | Radiology | General Surgery
Distinguished in Arterial Embolism
Dr. Fred A. Weaver
Vascular Surgery | Radiology | General Surgery

USC Care Medical Group Inc

1520 San Pablo St, Fl 4, 
Los Angeles, CA 
 (60.6 miles away)
800-872-2273
Languages Spoken:
English
See accepted insurances

Fred Weaver is a Vascular Surgeon and a Radiologist in Los Angeles, California. Dr. Weaver is rated as a Distinguished provider by MediFind in the treatment of Arterial Embolism. His top areas of expertise are Thoracic Aortic Aneurysm, Abdominal Aortic Aneurysm (AAA), Carotid Artery Disease, Aneurysm Repair, and Stent Placement.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jain's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile